A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP)

NCT01907009 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

29

Enrollment

OTHER

Sponsor class

Stopped Early termination

Conditions

Castrate Resistant Prostate Cancer

Interventions

DRUG: Melphalan
DRUG: Lenograstim

Sponsor

Barts & The London NHS Trust